Literature DB >> 11714833

Skin allograft maintenance in a new synchimeric model system of tolerance.

N N Iwakoshi1, T G Markees, N Turgeon, T Thornley, A Cuthbert, J Leif, N E Phillips, J P Mordes, D L Greiner, A A Rossini.   

Abstract

Treatment of mice with a single donor-specific transfusion plus a brief course of anti-CD154 mAb uniformly induces donor-specific transplantation tolerance characterized by the deletion of alloreactive CD8+ T cells. Survival of islet allografts in treated mice is permanent, but skin grafts eventually fail unless recipients are thymectomized. To analyze the mechanisms underlying tolerance induction, maintenance, and failure in euthymic mice we created a new analytical system based on allo-TCR-transgenic hemopoietic chimeric graft recipients. Chimeras were CBA (H-2(k)) mice engrafted with small numbers of syngeneic TCR-transgenic KB5 bone marrow cells. These mice subsequently circulated a self-renewing trace population of anti-H-2(b)-alloreactive CD8+ T cells maturing in a normal microenvironment. With this system, we studied the maintenance of H-2(b) allografts in tolerized mice. We documented that alloreactive CD8+ T cells deleted during tolerance induction slowly returned toward pretreatment levels. Skin allograft rejection in this system occurred in the context of 1) increasing numbers of alloreactive CD8+ cells; 2) a decline in anti-CD154 mAb concentration to levels too low to inhibit costimulatory functions; and 3) activation of the alloreactive CD8+ T cells during graft rejection following deliberate depletion of regulatory CD4+ T cells. Rejection of healed-in allografts in tolerized mice appears to be a dynamic process dependent on the level of residual costimulation blockade, CD4+ regulatory cells, and activated alloreactive CD8+ thymic emigrants that have repopulated the periphery after tolerization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714833      PMCID: PMC3896094          DOI: 10.4049/jimmunol.167.11.6623

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Prolonged skin allograft survival in mice treated with Flt3-ligand-induced dendritic cells and anti-CD154 monoclonal antibody.

Authors:  T G Markees; N E Phillips; E J Gordon; R J Noelle; C Maliszewski; J P Mordes; D L Greiner; A A Rossini
Journal:  Transplant Proc       Date:  1999 Feb-Mar       Impact factor: 1.066

Review 2.  Induction of islet transplantation tolerance using donor specific transfusion and anti-CD154 monoclonal antibody.

Authors:  A A Rossini; J P Mordes; T G Markees; N E Phillips; E J Gordon; D L Greiner
Journal:  Transplant Proc       Date:  1999 Feb-Mar       Impact factor: 1.066

3.  Improved skin allograft tolerance induced by treatment with donor splenocytes and an extended course of anti-CD154 monoclonal antibody.

Authors:  T Markees; N Phillips; E Gordon; R J Noelle; J P Mordes; D L Greiner; A A Rossini
Journal:  Transplant Proc       Date:  1998-08       Impact factor: 1.066

Review 4.  The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells.

Authors:  M F Mackey; R J Barth; R J Noelle
Journal:  J Leukoc Biol       Date:  1998-04       Impact factor: 4.962

Review 5.  The lost chord: microchimerism and allograft survival.

Authors:  T E Starzl; A J Demetris; N Murase; M Trucco; A W Thomson; A S Rao
Journal:  Immunol Today       Date:  1996-12

6.  Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.

Authors:  B R Blazar; P A Taylor; A Panoskaltsis-Mortari; J Buhlman; J Xu; R A Flavell; R Korngold; R Noelle; D A Vallera
Journal:  J Immunol       Date:  1997-01-01       Impact factor: 5.422

7.  The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo.

Authors:  M Niimi; T C Pearson; C P Larsen; D Z Alexander; D Hollenbaugh; A Aruffo; P S Linsley; E Thomas; K Campbell; W C Fanslow; R S Geha; P J Morris; K J Wood
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

8.  Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4.

Authors:  T G Markees; N E Phillips; E J Gordon; R J Noelle; L D Shultz; J P Mordes; D L Greiner; A A Rossini
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

Review 9.  Induction of immunologic tolerance for transplantation.

Authors:  A A Rossini; D L Greiner; J P Mordes
Journal:  Physiol Rev       Date:  1999-01       Impact factor: 37.312

10.  Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance.

Authors:  T Wekerle; M H Sayegh; J Hill; Y Zhao; A Chandraker; K G Swenson; G Zhao; M Sykes
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

View more
  22 in total

Review 1.  T-cell activation and transplantation tolerance.

Authors:  Bhavana Priyadharshini; Dale L Greiner; Michael A Brehm
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

Review 2.  Genetic separation of the transplantation tolerance and autoimmune phenotypes in NOD mice.

Authors:  Todd Pearson; Thomas G Markees; David V Serreze; Melissa A Pierce; Linda S Wicker; Laurence B Peterson; Leonard D Shultz; John P Mordes; Aldo A Rossini; Dale L Greiner
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

3.  Requirements for induction and maintenance of peripheral tolerance in stringent allograft models.

Authors:  Masayuki Sho; Koji Kishimoto; Hiroshi Harada; Mauren Livak; Alberto Sanchez-Fueyo; Akira Yamada; Xin Xiao Zheng; Terry B Strom; Giacomo P Basadonna; Mohamed H Sayegh; David M Rothstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

4.  TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts.

Authors:  Thomas B Thornley; Michael A Brehm; Thomas G Markees; Leonard D Shultz; John P Mordes; Raymond M Welsh; Aldo A Rossini; Dale L Greiner
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

5.  Rapid quantification of naive alloreactive T cells by TNF-alpha production and correlation with allograft rejection in mice.

Authors:  Michael A Brehm; Julie Mangada; Thomas G Markees; Todd Pearson; Keith A Daniels; Thomas B Thornley; Raymond M Welsh; Aldo A Rossini; Dale L Greiner
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

6.  Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance.

Authors:  Thomas B Thornley; Nancy E Phillips; Britte C Beaudette-Zlatanova; Thomas G Markees; Kapil Bahl; Michael A Brehm; Leonard D Shultz; Evelyn A Kurt-Jones; John P Mordes; Raymond M Welsh; Aldo A Rossini; Dale L Greiner
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

Review 7.  Hematopoietic stem cell infusion/transplantation for induction of allograft tolerance.

Authors:  Jose M M Granados; Gilles Benichou; Tatsuo Kawai
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

8.  Alloreactive CD8 T cells rescued from apoptosis during co-stimulation blockade by Toll-like receptor stimulation remain susceptible to Fas-induced cell death.

Authors:  Bhavana Priyadharshini; Thomas B Thornley; Keith A Daniels; Amy Cuthbert; Raymond M Welsh; Dale L Greiner; Michael A Brehm
Journal:  Immunology       Date:  2013-04       Impact factor: 7.397

Review 9.  Induction of tolerance for islet transplantation for type 1 diabetes.

Authors:  Edward Seung; John P Mordes; Dale L Greiner; Aldo A Rossini
Journal:  Curr Diab Rep       Date:  2003-08       Impact factor: 4.810

10.  Idd loci synergize to prolong islet allograft survival induced by costimulation blockade in NOD mice.

Authors:  Julie Mangada; Todd Pearson; Michael A Brehm; Linda S Wicker; Laurence B Peterson; Leonard D Shultz; David V Serreze; Aldo A Rossini; Dale L Greiner
Journal:  Diabetes       Date:  2008-11-04       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.